Table 1 Efficacy inputs for migraine treatments in the economic model
Results over 12 weeks of treatment, with standard error (SE) | TF3+ EM,  ≥ 50% reduction in MMDs | TF3+ CM,  ≥ 30% reduction in MMDs | TF3+ CM,  ≥ 50% reduction in MMDs (scenario) |
|---|---|---|---|
Responder rate, BSC, % | 9.6 (2.0) | 23.2 (4.6) | 8.9 (1.8a) |
Responder rate, eptinezumab 100mg, % | 40.0 (8.0) | 63.4 (12.9) | 30.4 (6.1a) |
Change from baseline in MMDs, BSC responders | -5.82 (1.50) | -8.80 (1.99) | -10.45 (1.41) |
Change from baseline in MMDs, eptinezumab 100 mg responders | -6.82 (0.92) | -9.93 (1.41) | -12.68 (1.40) |
Change from baseline in MMDs, BSC non-responders | -1.31 (0.84) | -0.85 (1.42) | -1.94 (0.96) |
Change from baseline in MMDs, eptinezumab 100 mg non-responders | -1.39 (1.18) | -1.71 (2.28) | -4.52 (1.17) |